MARLBOROUGH, Mass.,
March 16, 2017 /PRNewswire/ -- Today,
the National Institute for Health and Care Excellence (NICE) issued
medical technology guidance recommending the use of Boston
Scientific Corporation (NYSE: BSX) cardiac resynchronization
therapy defibrillators (CRT-D) powered by EnduraLife™ Battery
Technology for treating patients with heart failure.
In their evaluation, NICE – which provides evidenced-based
guidance to improve health and social care in the National Health
Service (NHS) in the United
Kingdom – concluded that the extended battery life observed
with Boston Scientific EnduraLife-powered CRT-Ds is likely to reduce the
number of avoidable replacement procedures a patient may have to
undergo, thereby offering improved outcomes for patients and
potential savings to the NHS in England of approximately £6 million in the
first five years.
The savings were calculated by modeling the costs associated
with early replacement procedures, such as a reduction in hospital
admissions, bed days and procurement costs. Fewer replacement
procedures also equate to a reduction in associated costs accrued
from post-operative complications and infections – both of which
also have a measurable impact on morbidity and mortality.
"The NICE guidance reinforces the multi-faceted importance of
battery longevity in devices treating patients with heart failure
and life-threatening ventricular arrhythmias," said Dr.
Jay Wright, consultant cardiologist,
Liverpool Heart and Chest Hospital, Liverpool, United Kingdom. "Additionally, the
reduction in replacement procedures and potential savings
identified within the guidance could offer longer-term relief to
NHS providers who have recently seen an increase in the number of
patients requiring further in-hospital treatment."
The NICE medical technologies advisory committee found that the
evidence from 16 independent clinical and economic studies
supported a case for adoption and concluded that EnduraLife-powered
CRT-Ds have a greater battery capacity and longer battery life
compared with other CRT-Ds reviewed.
"Battery life should be a key consideration in cardiac device
selection for the millions of patients who rely on them daily,"
said Kenneth Stein, M.D., senior
vice president and chief medical officer, Global Health Policy and
Rhythm Management, Boston Scientific. "We are proud to have our
EnduraLife Battery Technology recognized by NICE's evidence-based
review process and available for the benefit of patients and the
healthcare system at large."
EnduraLife Battery Technology, which has nearly two times the
usable battery capacity as certain competitive
devices[i],[ii] and is packaged in a device up to 18
percent smaller than other CRT-Ds[iii],[iv],[v], was
introduced in the company's line of CRT-Ds in 2008.
For more information on the NICE guidance,
visit https://www.nice.org.uk/guidance/mtg33.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology
leader for more than 35 years, we advance science for life by
providing a broad range of high performance solutions that address
unmet patient needs and reduce the cost of healthcare. For more
information, visit www.bostonscientific.com and connect on Twitter
and Facebook.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like
"anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements
are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be
guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding our business plans, clinical trials, regulatory approvals
and product performance and impact. If our underlying
assumptions turn out to be incorrect, or if certain risks or
uncertainties materialize, actual results could vary materially
from the expectations and projections expressed or implied by our
forward-looking statements. These factors, in some cases,
have affected and in the future (together with other factors) could
affect our ability to implement our business strategy and may cause
actual results to differ materially from those contemplated by the
statements expressed in this press release. As a result,
readers are cautioned not to place undue reliance on any of our
forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All
of these factors are difficult or impossible to predict accurately
and many of them are beyond our control. For a further list
and description of these and other important risks and
uncertainties that may affect our future operations, see Part I,
Item 1A – Risk Factors in our most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, which
we may update in Part II, Item 1A – Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to
publicly update or revise any forward-looking statements to reflect
any change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document.
CONTACTS:
Media:
Laura Aumann
Boston Scientific Corporation
(651) 582-4251 (office)
Laura.Aumann@bsci.com
European Media:
Chiara Ennas
Boston Scientific Corporation
+44 (0) 1442 411618 (office)
Chiara.Ennas@bsci.com
Susie Lisa, CFA
Investor Relations
Boston Scientific Corporation
(508) 683-5565 (office)
investor_relations@bsci.com
[i] Medtronic Evera XT VR DVBB2D4 Device Manual page
25.
[ii] Boston Scientific Implantable Cardioverter
Defibrillator Physician's Technical Manual 359050-003 EN US 2014-01
page 30.
[iii] Boston Scientific CRT-D Physician's Technical
Manual 359401-002 EN US 2015-10.
[iv] Quadra AssuraTM Cardiac
Resynchronisation Therapy Defibrillator (CRT-D) product
manual. https://www.sjm.com/en/professionals/resources-and-reimbursement/technical-resources/cardiac-rhythm-management/cardiac-resynchronization-therapy-crt-devices/crt-defibrillator/quadra-assura-cardiac-resynchronization-therapy-defibrillator-crt-d.
Updated August 19, 2013. Accessed
February 28, 2017.
[v] Quadra Assura MPTM Cardiac
Resynchronisation Therapy Defibrillator (CRT-D) product
manual. https://www.sjmglobal.com/en-int/professionals/resources-and-reimbursement/technical-resources/cardiac-rhythm-management/cardiac-resynchronization-therapy-crt-devices/crt-defibrillator/quadra-assura-mp-cardiac-resynchronisation-therapy-defibrillator-crt-d-cd3371-40c-and-cd3371-40qc-with-parylene-coating.
Updated December 8, 2015. Accessed
February 28, 2017.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nice-recommends-boston-scientific-crt-d-devices-powered-by-enduralife-battery-technology-for-treatment-of-heart-failure-300425301.html
SOURCE Boston Scientific Corporation